These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27650678)

  • 1. Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).
    Davies KR; Brewster AM; Bedrosian I; Parker PA; Crosby MA; Peterson SK; Shen Y; Volk RJ; Cantor SB
    Breast Cancer Res; 2016 Sep; 18(1):93. PubMed ID: 27650678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis.
    Portschy PR; Kuntz KM; Tuttle TM
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25031308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness Analysis of Contralateral Prophylactic Mastectomy Compared to Unilateral Mastectomy with Routine Surveillance for Unilateral, Sporadic Breast Cancer.
    Keskey RC; LaJoie AS; Sutton BS; Kim IK; Cheadle WG; McMasters KM; Ajkay N
    Ann Surg Oncol; 2017 Dec; 24(13):3903-3910. PubMed ID: 29039025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis.
    Lester-Coll NH; Lee JM; Gogineni K; Hwang WT; Schwartz JS; Prosnitz RG
    Breast Cancer Res Treat; 2015 Jul; 152(1):217-226. PubMed ID: 26062750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
    Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
    Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.
    Wong SM; Freedman RA; Sagara Y; Aydogan F; Barry WT; Golshan M
    Ann Surg; 2017 Mar; 265(3):581-589. PubMed ID: 28169929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer.
    Zendejas B; Moriarty JP; O'Byrne J; Degnim AC; Farley DR; Boughey JC
    J Clin Oncol; 2011 Aug; 29(22):2993-3000. PubMed ID: 21690472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?
    Tesson S; Richards I; Porter D; Phillips KA; Rankin N; Costa D; Musiello T; Marven M; Butow P
    Breast; 2017 Feb; 31():233-240. PubMed ID: 27969575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.
    Hegde JV; Wang X; Attai DJ; DiNome ML; Kusske A; Hoyt AC; Hurvitz SA; Weidhaas JB; Steinberg ML; McCloskey SA
    Clin Breast Cancer; 2018 Apr; 18(2):e205-e218. PubMed ID: 29050918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy.
    Davies KR; Cantor SB; Brewster AM
    Int J Womens Health; 2015; 7():181-7. PubMed ID: 25678823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology.
    Bjelic-Radisic V; Singer C; Tamussino K; Kölbl H; Petru E; Volgger B; Polterauer S; Oppelt P; Sevelda P; Bogner G; Marth C;
    Wien Klin Wochenschr; 2019 May; 131(9-10):233-236. PubMed ID: 30887224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.
    Rosenberg SM; Sepucha K; Ruddy KJ; Tamimi RM; Gelber S; Meyer ME; Schapira L; Come SE; Borges VF; Golshan M; Winer EP; Partridge AH
    Ann Surg Oncol; 2015 Nov; 22(12):3809-15. PubMed ID: 25930247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
    Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
    J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer.
    Roberts A; Habibi M; Frick KD
    Ann Surg Oncol; 2014 Jul; 21(7):2209-17. PubMed ID: 24633665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting women's intentions for contralateral prophylactic mastectomy: An application of an extended theory of planned behaviour.
    Richards I; Tesson S; Porter D; Phillips KA; Rankin N; Musiello T; Marven M; Butow P
    Eur J Oncol Nurs; 2016 Apr; 21():57-65. PubMed ID: 26952679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer.
    Jagsi R; Hawley ST; Griffith KA; Janz NK; Kurian AW; Ward KC; Hamilton AS; Morrow M; Katz SJ
    JAMA Surg; 2017 Mar; 152(3):274-282. PubMed ID: 28002555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
    Wang F; Amara D; Peled AW; Sbitany H; Foster RD; Ewing CA; Alvarado M; Esserman LJ
    Ann Surg Oncol; 2015 Oct; 22(10):3338-45. PubMed ID: 26215194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.
    King TA; Sakr R; Patil S; Gurevich I; Stempel M; Sampson M; Morrow M
    J Clin Oncol; 2011 Jun; 29(16):2158-64. PubMed ID: 21464413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.